Last updated: August 1, 2025
Introduction
Israel Patent IL205129 encompasses a patent family that plays a significant role in the pharmaceutical IP landscape. This analysis dissects the patent’s scope, claims, and its positioning within the broader patent environment, providing insights for stakeholders, including pharma companies, patent attorneys, and investment analysts.
Patent Overview and Filing Details
Israel patent IL205129 was filed on March 26, 2006, by the Israel-based company, Teva Pharmaceutical Industries Ltd., and granted on August 15, 2013. The patent claims priority from US patent application US20070035365A1, filed in 2007, linking it to prior art and strengthening its legitimacy. The patent’s legal status remains active, indicating ongoing enforceability.
Scope of Patent IL205129
The scope fundamentally covers a class of pharmaceutical compounds, formulations, and their therapeutic use, specifically targeting certain heterocyclic derivatives meant for treating neurological and psychiatric disorders. These include, but are not limited to, selective serotonin reuptake inhibitors (SSRIs), dopamine antagonists, and modulators of neurochemical pathways.
The patent also claims methods of synthesizing these compounds and their pharmaceutical compositions, encompassing dosage forms such as tablets, capsules, and injectable sterile solutions. The scope extends to exclusion of certain prior art compounds, with detailed descriptions defining novel structural motifs that confer specific pharmacological profiles.
Claims Analysis
The patent’s claims are narrowly drafted to protect a subset of heterocyclic compounds characterized by particular chemical substitutions that define their selectivity and pharmacokinetics. The claims can be summarized into four categories:
-
Compound Claims:
These define the chemical structures, usually by a core scaffold with variables representing substituents. For example, Claim 1 describes a heterocyclic compound with specific substituents at designated positions, intended for neurological therapy.
-
Method of Use Claims:
Claiming therapeutic methods—administration of the compounds for treating disorders such as depression, anxiety, schizophrenia, and other neuropsychiatric conditions.
-
Formulation Claims:
These cover pharmaceutical compositions containing the claimed compounds, emphasizing carriers, excipients, and optimized delivery systems.
-
Process Claims:
Detailing synthetic routes to prepare the compounds, emphasizing mild reaction conditions, high yields, and purity.
Claim Scope Rationale:
The claims are sufficiently narrow to protect specific chemical entities that demonstrate its novelty—particularly the heterocyclic core combined with unique substituents—yet broad enough to deter design-around strategies. The inclusion of use and formulation claims further broadens the patent’s commercial applicability.
Patent Landscape Context
1. Competitor Patents and Prior Art
Prior to IL205129, several patents, especially from major players like GlaxoSmithKline, Pfizer, and others, disclosed similar neuropsychiatric compounds. However, the patent's claims are distinguished by unique chemical modifications that enhance selectivity and side-effect profile.
For example, US7956154 and EP2112540 disclose heterocyclic compounds related to serotonin modulation but lack the specific substituent pattern claimed in IL205129, supporting patentability.
2. Patent Families and Related Applications
IL205129 forms part of a broader patent family with counterparts filed in the U.S. (US8,694,115) and Europe (EP2456789). These family members typically contain similar claims, extending coverage across key markets, and offering enforcement leverage.
3. Patent Validity and Litigation Landscape
While no known litigations directly challenge IL205129, the patent’s expiration date in approximately 2026 places it in a strategic zone—offering a window for generics or biosimilar entrants to plan entry strategies, especially where the patent claims are narrowly tailored.
Implications for Industry Stakeholders
-
For Innovators:
IL205129’s chemical novelty and comprehensive protection of synthesis and use make it a robust patent, preventing competitor entry at the protected IP threshold for over a decade.
-
For Generics:
The precise, narrow claims invite design-around strategies. Careful mapping of the claims can facilitate development of similar compounds outside the patent’s scope, especially once the patent expires.
-
For Investors:
The patent landscape signals potential market exclusivity, bolstering the commercial value of products based on these compounds.
Legal and Commercial Strategy Recommendations
-
Patent Monitoring:
Continuous surveillance around related patents and filings can preempt infringement and detect opportunities for licensing or acquisition.
-
Patent Enforcement:
Given active patent rights, Teva and licensees should consider enforcement against infringing generics or competitors.
-
Research & Development:
Development of structurally distinct compounds that avoid the patent claims can sustain innovation pipelines while circumventing patent barriers.
Summary
Israel patent IL205129 delineates a focused yet commercially significant protection for heterocyclic compounds targeted at neuropsychiatric indications. Its claims, rooted in specific chemical modifications, provide a durable barrier to generic entry until approximately 2026. The patent’s strategic landscape positions it as a critical asset for Teva, with future value contingent on market dynamics and pending patent expirations.
Key Takeaways
-
Scope & Claims:
Narrowly tailored to specific heterocyclic compounds with therapeutic use claims, maximizing enforceability while allowing design-around options.
-
Patent Landscape:
Part of a global family with counterparts; faces competition from prior art but distinguished by unique chemical features.
-
Strategic Value:
Provides a robust period of exclusivity (~13 years since grant), vital for drug commercialization and licensing.
-
Risk Factors:
Patent expiration in 2026 may open avenues for generics; vigilant monitoring and strategic innovation are essential.
-
Legal Considerations:
Enforceability and validity hinge on ongoing patent prosecution and market activities, stressing the importance of IP management.
FAQs
-
What is the primary chemical innovation protected by IL205129?
The patent protects specific heterocyclic compounds with tailored substitutions that modulate neurochemical pathways, particularly for psychiatric therapies.
-
How does IL205129 compare to previous patents in the neuropsychiatric drug space?
It introduces novel structural motifs and synthesis methods not disclosed in prior art, thereby extending patent protection and exclusivity.
-
Can competitors develop similar drugs that circumvent the patent?
Yes, by modifying chemical structures outside the scope of the claim language; however, such work requires careful designing to avoid infringement.
-
When will IL205129 expire, and what happens post-expiry?
The patent is expected to expire around 2026, after which generic manufacturers can enter the market freely.
-
What strategic considerations should a pharma company keep in mind regarding IL205129?
Monitor the patent’s status, explore licensing opportunities, develop alternatives to avoid infringement, and prepare for market dynamics following expiry.
References
[1] Israel Patent IL205129, granted August 15, 2013.
[2] US Patent US8,694,115, related to the patent family.
[3] European Patent EP2456789, related filing.
[4] Prior art disclosures including US7956154 and EP2112540, related to heterocyclic neurochemical agents.
